Hikma Pharmaceuticals has agreed to acquire the rights to 17 branded pharmaceutical products from Takeda, enhancing its manufacturing capabilities and market presence in the MENA region.

Target Information

Hikma Pharmaceuticals PLC (Hikma) is a multinational pharmaceutical company based in London, renowned for its strong presence in the MENA (Middle East and North Africa) region. As part of a strategic partnership with Takeda Pharmaceuticals International AG (Takeda), Hikma has been licensing, commercializing, and, in select cases, manufacturing a diverse portfolio of pharmaceutical products. The current portfolio includes 17 brands focused on key therapeutic areas such as cardiovascular health, diabetes management, gastroenterology, and pain relief.

With this acquisition, Hikma will obtain the rights to these marketed brands, which are integral to its operations in MENA. This move is a crucial step towards enhancing Hikma's ability to ensure a steady supply of essential medications to patients across the region, as it plans to gradually transition the manufacturing of these products in-house.

Industry Overview

The pharmaceutical sector in the MENA region is experiencing substantial growth, driven by increasing healthcare demands associated with rising populations and the prevalence of chronic diseases.